Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214532) titled 'Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Natera, Inc.
Condition:
Breast Neoplasms
Carcinoma, Ductal, Breast
Receptors, Estrogen (for ER-positive Requirement)
Intervention:
Device: ctDNA-Guided Treatment Strategy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 15, 2025
Target Sample Size: 725
To know more, visit https://clinicaltrials.gov/study/NCT07214532
Publi...